JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB80276

Anti-PD-L1 antibody [MIH6] - Low endotoxin, Azide free

4

(5 Reviews)

|

(15 Publications)

Rat Monoclonal PD-L1 antibody. Carrier free. Suitable for Flow Cyt and reacts with Mouse samples. Cited in 15 publications.

View Alternative Names

CD274, B7h1, Pdcd1l1, Pdcd1lg1, Pdl1, Cd274, Programmed cell death 1 ligand 1, PD-L1, PDCD1 ligand 1, Programmed death ligand 1, B7 homolog 1, B7-H1

1 Images
Flow Cytometry - Anti-PD-L1 antibody [MIH6] - Low endotoxin, Azide free (AB80276)
  • Flow Cyt

Supplier Data

Flow Cytometry - Anti-PD-L1 antibody [MIH6] - Low endotoxin, Azide free (AB80276)

C57BL/6 mouse splenocytes were stained with ab80276 (purple filled histogram) or purified rat IgG2a, κ isotype control (black dashed line open histogram), followed by anti-Rat IgG PE.

Key facts

Host species

Rat

Clonality

Monoclonal

Clone number

MIH6

Isotype

IgG2a

Light chain type

kappa

Carrier free

Yes

Reacts with

Mouse

Applications

Flow Cyt

applications

Immunogen

The exact immunogen used to generate this antibody is proprietary information.

style
left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "FlowCyt" : {"fullname" : "Flow Cytometry", "shortname":"Flow Cyt"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Mouse": { "FlowCyt-species-checked": "testedAndGuaranteed", "FlowCyt-species-dilution-info": "", "FlowCyt-species-notes": "<p>Use = 0.5 μg per million cells in 100 μl volume or 100 μl of whole blood.</p>" } } }
style
left-column

Product details

Please note the manufacture has changed and this item is currently only recommended for Flow Cytometry.
style
left-column

Properties and storage information

Form
Liquid
Purification technique
Affinity purification
Purification notes
<0.01 EU/ug Endotoxin (LAL).
Storage buffer
pH: 7.2 Constituents: PBS
Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle
style
left-column

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

PD-L1 also known as Programmed Death-Ligand 1 or CD274 is a protein involved in immune modulation. Mechanically PD-L1 interacts with its receptors particularly PD-1 to regulate cellular immune responses. This transmembrane protein has a calculated molecular weight of approximately 33 kDa. PD-L1 is expressed on various cell types including tumor cells and immune cells such as dendritic cells macrophages and B cells. Its expression is often upregulated in response to inflammatory cytokines.
Biological function summary

PD-L1 plays a central role in immune evasion mechanisms utilized by tumors. It is not part of a larger protein complex but directly interacts with PD-1 and CD80. When PD-L1 binds to PD-1 it sends inhibitory signals leading to decreased T cell activation and proliferation allowing cancer cells to avoid immune destruction. PD-L1 expression provides a mechanism for tumors to suppress immune surveillance facilitating tumor progression.

Pathways

PD-L1 is integral to the immune checkpoint pathway which is an important regulator of immune response. The interaction between PD-L1 and PD-1 provides a mechanism for immune tolerance which is part of the broader adaptive immune system pathway. PD-L1 is related to other immune checkpoint proteins such as CTLA-4 in its function to limit autoreactivity and promote immune homeostasis.

PD-L1 is most associated with cancer particularly in tumors such as melanoma and non-small cell lung cancer. PD-L1 expression on tumor cells often correlates with poor prognosis. PD-L1 directly interacts with PD-1 in these cancers a target for immunotherapies such as checkpoint inhibitors which aim to block this interaction and restore immune activity against tumors. PD-L1 involvement extends to autoimmune disorders where altered expression can impact tolerance and lead to immune-related tissue damage.
style
left-column
style
left-column

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:
style
left-column

Target data

Plays a critical role in induction and maintenance of immune tolerance to self (PubMed : 11238124). As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response (PubMed : 11238124). Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10) (PubMed : 11015443, PubMed : 12719480).. The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survival (PubMed : 12218188, PubMed : 27281199). The interaction with PDCD1/PD-1 inhibits cytotoxic T lymphocytes (CTLs) effector function (PubMed : 12218188). The blockage of the PDCD1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy (PubMed : 12218188).
See full target information Cd274
style
left-column

Publications (15)

Recent publications for all applications. Explore the full list and refine your search

Molecular therapy : the journal of the American Society of Gene Therapy 29:2335-2349 PubMed33647456

2021

Pre-conditioning modifies the TME to enhance solid tumor CAR T cell efficacy and endogenous protective immunity.

Applications

Unspecified application

Species

Unspecified reactive species

John P Murad,Dileshni Tilakawardane,Anthony K Park,Lupita S Lopez,Cari A Young,Jackson Gibson,Yukiko Yamaguchi,Hee Jun Lee,Kelly T Kennewick,Brenna J Gittins,Wen-Chung Chang,Chau P Tran,Catalina Martinez,Anna M Wu,Robert E Reiter,Tanya B Dorff,Stephen J Forman,Saul J Priceman

Journal for immunotherapy of cancer 8: PubMed33203663

2020

Nuclear imaging-guided PD-L1 blockade therapy increases effectiveness of cancer immunotherapy.

Applications

Unspecified application

Species

Unspecified reactive species

Hannan Gao,Yue Wu,Jiyun Shi,Xin Zhang,Tianyu Liu,Biao Hu,Bing Jia,Yakun Wan,Zhaofei Liu,Fan Wang

Oncoimmunology 9:1831153 PubMed33110706

2020

Small-molecule PD-L1 inhibitor BMS1166 abrogates the function of PD-L1 by blocking its ER export.

Applications

Unspecified application

Species

Unspecified reactive species

Fang-Fang Chen,Zheng Li,Dawei Ma,Qiang Yu

Nature communications 11:1335 PubMed32165639

2020

Cancer immune control needs senescence induction by interferon-dependent cell cycle regulator pathways in tumours.

Applications

Unspecified application

Species

Unspecified reactive species

Ellen Brenner,Barbara F Schörg,Fatima Ahmetlić,Thomas Wieder,Franz Joachim Hilke,Nadine Simon,Christopher Schroeder,German Demidov,Tanja Riedel,Birgit Fehrenbacher,Martin Schaller,Andrea Forschner,Thomas Eigentler,Heike Niessner,Tobias Sinnberg,Katharina S Böhm,Nadine Hömberg,Heidi Braumüller,Daniel Dauch,Stefan Zwirner,Lars Zender,Dominik Sonanini,Albert Geishauser,Jürgen Bauer,Martin Eichner,Katja J Jarick,Andreas Beilhack,Saskia Biskup,Dennis Döcker,Dirk Schadendorf,Leticia Quintanilla-Martinez,Bernd J Pichler,Manfred Kneilling,Ralph Mocikat,Martin Röcken

The Journal of clinical investigation 130:451-465 PubMed31613799

2019

Targeting tumor-intrinsic hexosamine biosynthesis sensitizes pancreatic cancer to anti-PD1 therapy.

Applications

Unspecified application

Species

Unspecified reactive species

Nikita S Sharma,Vineet K Gupta,Vanessa T Garrido,Roey Hadad,Brittany C Durden,Kousik Kesh,Bhuwan Giri,Anthony Ferrantella,Vikas Dudeja,Ashok Saluja,Sulagna Banerjee

Scientific reports 9:4712 PubMed30886310

2019

RNAi-Mediated PD-L1 Inhibition for Pancreatic Cancer Immunotherapy.

Applications

Unspecified application

Species

Unspecified reactive species

Byunghee Yoo,Veronica Clavijo Jordan,Patrick Sheedy,Ann-Marie Billig,Alana Ross,Pamela Pantazopoulos,Zdravka Medarova

International journal of immunopathology and pharmacology 33:2058738418820760 PubMed30791745

2019

Blocking of checkpoint receptor PD-L1 aggravates osteoarthritis in macrophage-dependent manner in the mice model.

Applications

Unspecified application

Species

Unspecified reactive species

Shenghou Liu,Jiqiang Mi,Wenguang Liu,Shipeng Xiao,Chunzheng Gao

Journal of Cancer 9:4374-4381 PubMed30519342

2018

PD-1 Blockade Overcomes Adaptive Immune Resistance in Treatment with Anchored-GM-CSF Bladder Cancer Cells Vaccine.

Applications

Unspecified application

Species

Unspecified reactive species

Xinji Zhang,Xiaojun Shi,Jinlong Li,Lijun Mo,Zhiming Hu,Jimin Gao,Shihao Wu,Zhaolin Long

Nano letters 18:6195-6206 PubMed30259750

2018

Personalized Tumor RNA Loaded Lipid-Nanoparticles Prime the Systemic and Intratumoral Milieu for Response to Cancer Immunotherapy.

Applications

Unspecified application

Species

Unspecified reactive species

Elias J Sayour,Adam Grippin,Gabriel De Leon,Brian Stover,Maryam Rahman,Aida Karachi,Brandon Wummer,Ginger Moore,Paul Castillo-Caro,Kristianna Fredenburg,Matthew R Sarkisian,Jianping Huang,Loic P Deleyrolle,Bikash Sahay,Sheila Carrera-Justiz,Hector R Mendez-Gomez,Duane A Mitchell

Cancer immunology research 6:1459-1471 PubMed30209062

2018

Stromal Fibroblasts Mediate Anti-PD-1 Resistance via MMP-9 and Dictate TGFβ Inhibitor Sequencing in Melanoma.

Applications

Unspecified application

Species

Unspecified reactive species

Fei Zhao,Kathy Evans,Christine Xiao,Nicholas DeVito,Balamayooran Theivanthiran,Alisha Holtzhausen,Peter J Siska,Gerard C Blobe,Brent A Hanks
View all publications
style
left-column
style
left-column
style
right-column

Alternative Products

Primary Antibodies

AB252436

Anti-PD-L1 antibody [EPR23546-160]

RabMAb|Recombinant|20ul selling size

Immunocytochemistry/ Immunofluorescence - Anti-PD-L1 antibody [EPR23546-160] (AB252436)

  • 4
  • 1
Multiplex Kits

AB239749

PD-L1 Antibody Panel (28-8, 73-10, SP142, CAL10)

Recombinant

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - PD-L1 Antibody Panel (28-8, 73-10, SP142, CAL10) (AB239749)

  • 0
  • 0
Primary Antibodies

AB209960

Alexa Fluor® 647 Anti-PD-L1 antibody [28-8] - Extracellular domain

RabMAb|Recombinant

Immunocytochemistry/ Immunofluorescence - Alexa Fluor® 647 Anti-PD-L1 antibody [28-8] - Extracellular domain (AB209960)

  • 0
  • 0
Primary Antibodies

AB209959

Alexa Fluor® 488 Anti-PD-L1 antibody [28-8]

RabMAb|Recombinant

Flow Cytometry - Alexa Fluor® 488 Anti-PD-L1 antibody [28-8] (AB209959)

  • 5
  • 1
Primary Antibodies

AB213480

Anti-PD-L1 antibody [EPR20529]

RabMAb|Recombinant|KO Validated|20ul selling size

Immunocytochemistry/ Immunofluorescence - Anti-PD-L1 antibody [EPR20529] (AB213480)

  • 5
  • 5
Primary Antibodies

AB213524

Anti-PD-L1 antibody [EPR19759]

BOND RX™ Validated|RabMAb|Recombinant|KO Validated|20ul selling size

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PD-L1 antibody [EPR19759] (AB213524)

  • 5
  • 1
Primary Antibodies

AB205921

Anti-PD-L1 antibody [28-8]

BOND RX™ Validated|20ul selling size|Recombinant|KO Validated|Advanced Validation|RabMAb

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PD-L1 antibody [28-8] (AB205921)

  • 4
  • 15
Primary Antibodies

AB226766

Anti-PD-L1 antibody [73-10] - BSA and Azide free

BOND RX™ Validated|KO Validated|RabMAb|Recombinant

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PD-L1 antibody [73-10] - BSA and Azide free (AB226766)

  • 4
  • 1
Primary Antibodies

AB209889

Anti-PD-L1 antibody [28-8] - Low endotoxin, Azide free

BOND RX™ Validated|RabMAb|Recombinant|KO Validated

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PD-L1 antibody [28-8] - Low endotoxin, Azide free (AB209889)

  • 0
  • 0
Primary Antibodies

AB228415

Anti-PD-L1 antibody [73-10]

BOND RX™ Validated|KO Validated|RabMAb|Recombinant

Immunohistochemistry (Frozen sections) - Anti-PD-L1 antibody [73-10] (AB228415)

  • 5
  • 1
Primary Antibodies

AB274896

Alexa Fluor® 555 Anti-PD-L1 antibody [73-10]

BOND RX™ Validated|RabMAb|Recombinant|Trial Size

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Alexa Fluor® 555 Anti-PD-L1 antibody [73-10] (AB274896)

  • 4
  • 1
Primary Antibodies

AB228462

Anti-PD-L1 antibody [SP142] - C-terminal

BOND RX™ Validated|20ul selling size|RabMAb|Advanced Validation|Recombinant

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PD-L1 antibody [SP142] - C-terminal (AB228462)

  • 5
  • 2

Complementary Products

Secondary Antibodies

AB150077

Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488)

Immunocytochemistry/ Immunofluorescence - Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) (AB150077)

  • 5
  • 20
Primary Antibodies

AB217344

Anti-CD8 alpha antibody [EPR21769]

RabMAb|Recombinant

Flow Cytometry - Anti-CD8 alpha antibody [EPR21769] (AB217344)

  • 5
  • 6
Primary Antibodies

AB214421

Anti-PD1 antibody [EPR20665]

20ul selling size|RabMAb|Recombinant

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PD1 antibody [EPR20665] (AB214421)

  • 4
  • 3
Primary Antibodies

AB9485

Anti-GAPDH antibody - Loading Control

BOND RX™ Validated|Lab Essentials

Immunocytochemistry/ Immunofluorescence - Anti-GAPDH antibody - Loading Control (AB9485)

  • 5
  • 88

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com